Compare XPOF & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XPOF | XFOR |
|---|---|---|
| Founded | 2017 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 278.9M | 323.5M |
| IPO Year | 2021 | N/A |
| Metric | XPOF | XFOR |
|---|---|---|
| Price | $8.55 | $3.56 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | $10.86 | ★ $28.50 |
| AVG Volume (30 Days) | 400.0K | ★ 420.2K |
| Earning Date | 03-12-2026 | 03-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $315,135,000.00 | $33,979,000.00 |
| Revenue This Year | N/A | $1,266.01 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 2925.74 |
| 52 Week Low | $5.38 | $1.35 |
| 52 Week High | $18.87 | $17.96 |
| Indicator | XPOF | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 54.25 | 50.61 |
| Support Level | $8.10 | $3.65 |
| Resistance Level | $9.25 | $3.74 |
| Average True Range (ATR) | 0.42 | 0.17 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 45.83 | 58.14 |
Xponential Fitness Inc is a curator of boutique fitness brands. Its diversified portfolio of brands includes Club Pilates, a Pilates brand in the United States; CycleBar, an indoor cycling brand in the United States; StretchLab, a concept offering one-on-one and group stretching services; Row House, a high-energy, low-impact indoor rowing workout; AKT, a dance-based cardio workout combining toning, interval and circuit training; YogaSix a franchised yoga brand; Pure Barre, a total body workout that uses the ballet barre to perform small isometric movements; Stride, a treadmill-based cardio and strength training concept; Rumble, a boxing-inspired full-body workout; and BFT, a functional training and strength-based program. Its key revenue source is franchise income.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.